STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better

The BIO 2026 international conference in San Diego featured discussions on the growing influence of China in drug development and strategies to bolster the U.S. biotech industry. Executives expressed concerns about Washington's political landscape and pricing policies, while also emphasizing the need to rapidly integrate artificial intelligence to maintain a competitive advantage. Attendees observed presentations and engaged in conversations that highlighted both the opportunities and challenges facing the sector, with a particular focus on leveraging AI for innovation and market positioning. The event underscored a dual imperative for U.S. biotech: navigating regulatory and political environments while accelerating the adoption of advanced technologies like AI to drive future growth and development. Discussions also touched upon international collaboration and competition, with pavilions representing various countries showcasing their contributions and ambitions in the global biotechnology arena.